Free tool
FAERS Monitor: Zepzelca
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213702 or its brand name (Zepzelca, Lurbinectedin). Reports on generic versions are filed under their own applications.
Reports
1,169
Serious
937
80% of reports
Hospitalization
419
Death reported
286
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death150
- disease progression108
- neutropenia82
- off label use82
- nausea70
- thrombocytopenia60
- fatigue56
- febrile neutropenia47
- anaemia45
- asthenia45
- vomiting43
- injection site reaction36
- diarrhoea31
- acute kidney injury29
- dyspnoea29
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 54 |
| 2021 | 126 |
| 2022 | 244 |
| 2023 | 249 |
| 2024 | 180 |
| 2025 | 161 |
| 2026 | 150 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,990 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| disease progressionSignal | 108 | 16.4 | 13.7 | 1,558 |
| febrile neutropeniaSignal | 47 | 12.8 | 9.6 | 499 |
| neutropeniaSignal | 82 | 10.9 | 8.8 | 728 |
| thrombocytopeniaSignal | 60 | 9.7 | 7.5 | 459 |
| injection site reactionSignal | 36 | 9.4 | 6.8 | 263 |
| anaemiaSignal | 45 | 4.2 | 3.2 | 109 |
| acute kidney injurySignal | 29 | 3.4 | 2.4 | 47 |
| deathSignal | 150 | 3.1 | 2.7 | 225 |
| astheniaSignal | 45 | 2.2 | 1.6 | 27 |
| off label use | 82 | 1.7 | 1.4 | 23 |
| vomiting | 43 | 1.6 | 1.2 | 10 |
| nausea | 70 | 1.6 | 1.3 | 15 |
| fatigue | 56 | 1.3 | 1.0 | 4 |
| dyspnoea | 29 | 0.9 | 0.6 | 0 |
| diarrhoea | 31 | 0.9 | 0.6 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.